The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children

被引：21

作者：

Biss, T. T. ^{[1
]}

Avery, P. J. ^{[2
]}

Williams, M. D. ^{[3
]}

Brandao, L. R. ^{[4
]}

Grainger, J. D. ^{[5
]}

Kamali, F. ^{[1
]}

机构：

[1] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England

[2] Newcastle Univ, Sch Math & Stat, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England

[3] Birmingham Childrens Hosp, Dept Haematol, Birmingham, W Midlands, England

[4] Hosp Sick Children, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada

[5] Royal Manchester Childrens Hosp, Dept Haematol, Manchester M27 1HA, Lancs, England

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2013年 / 11卷 / 02期

关键词：

DOSE REQUIREMENT; POLYMORPHISMS; VARIANTS; OUTCOMES;

D O I：

10.1111/jth.12072

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

[No abstract available]

引用

页码：373 / 375

页数：3

共 9 条

[1]

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].

Aithal, GP ;

Day, CP ;

Kesteven, PJL ;

Daly, AK .

LANCET, 1999, 353 (9154) :717-719

[2]

VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children [J].

Biss, Tina T. ;

Avery, Peter J. ;

Brandao, Leonardo R. ;

Chalmers, Elizabeth A. ;

Williams, Michael D. ;

Grainger, John D. ;

Leathart, Julian B. S. ;

Hanley, John P. ;

Daly, Ann K. ;

Kamali, Farhad .

BLOOD, 2012, 119 (03) :868-873

[3]

CYP2D6 multiallelism [J].

Daly, AK ;

Steen, VM ;

Fairbrother, KS ;

Idle, JR .

CYTOCHROME P450, PT B, 1996, 272 :199-210

[4]

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy [J].

Higashi, MK ;

Veenstra, DL ;

Kondo, LML ;

Wittkowsky, AK ;

Srinouanprachanh, SL ;

Farin, FM ;

Rettie, AE .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13) :1690-1698

[5]

Warfarin dosing and cytochrome P4502C9 polymorphisms [J].

Joffe, HV ;

Xu, RL ;

Johnson, FB ;

Longtine, J ;

Kucher, N ;

Goldhaber, SZ .

THROMBOSIS AND HAEMOSTASIS, 2004, 91 (06) :1123-1128

[6]

An analysis of the relative effects of VKORCI and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients [J].

Meckley, Lisa M. ;

Wittkowsky, Ann K. ;

Rieder, Mark J. ;

Rettie, Allan E. ;

Veenstra, David L. .

THROMBOSIS AND HAEMOSTASIS, 2008, 100 (02) :229-239

[7]

Antithrombotic Therapy in Neonates and Children Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].

Monagle, Paul ;

Chan, Anthony K. C. ;

Goldenberg, Neil A. ;

Ichord, Rebecca N. ;

Journeycake, Janna M. ;

Nowak-Goettl, Ulrike ;

Vesely, Sara K. .

CHEST, 2012, 141 (02) :E737S-E801S

[8]

Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement [J].

Moreau, Caroline ;

Bajolle, Fanny ;

Siguret, Virginie ;

Lasne, Dominique ;

Golmard, Jean-Louis ;

Elie, Caroline ;

Beaune, Philippe ;

Cheurfi, Radhia ;

Bonnet, Damien ;

Loriot, Marie-Anne .

BLOOD, 2012, 119 (03) :861-867

[9]

Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer [J].

Ruud, Ellen ;

Holmstrom, Henrik ;

Bergan, Stein ;

Wesenberg, Finn .

PEDIATRIC BLOOD & CANCER, 2008, 50 (03) :710-713

← 1 →